Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Khondrion logo — Bringing energy to life

Khondrion

Bringing energy to life

Founded 2012 The Netherlands The Netherlands 7 employees Grant Biotechnology, Pharmaceutical

General Information

Company Name Khondrion
Founded Year 2012
Location The Netherlands The Netherlands +1
Employees 7
Industries Biotechnology, Pharmaceutical
Funding Stage Grant
Social

Get notified when Khondrion moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Khondrion

We are a clinical-stage pharmaceutical company discovering and developing therapies targeting mitochondrial disease. Founded by Professor Jan Smeitink, a world-leader in mitochondrial medicine, we are advancing our proprietary science through a wholly-owned clinical and preclinical small molecule pipeline of potential medicines. Our priority is to rapidly develop our pipeline to deliver transformative medicines for patients living with mitochondrial disease. Our in-house scientists are driving innovative research projects and building a portfolio of promising compounds. We have active discovery programmes underway developing new therapies, biomarkers, diagnostic applications and new read-out technologies in the field of mitochondrial diseases. Our lead pipeline asset, KH176, is a potential first-in-class oral small molecule in phase IIb clinical development to treat a range of mitochondrial diseases. It has been granted Orphan Drug Designation for MELAS (mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes) spectrum disorders and Leigh disease in Europe and for all inherited mitochondrial respiratory chain disorders in the US. We work in collaboration with patient organisations internationally as well as a global clinical and academic network to accelerate the discovery and development of our potential medicines for patients with mitochondrial diseases

No funding data available for Khondrion yet.

Get notified when Khondrion raises funding

Khondrion Alternatives & Competitors

Khondrion vs
Praxis Precision Medicines, Inc.
Praxis Precision Medicines, Inc. United States

The era of genetic neuroscience has arrived

IPO
244 employees
Biotechnology, Health Care
Khondrion vs
Kezar Life Sciences
Kezar Life Sciences United States

Pioneering first-in-class, small-molecule therapies for immune-mediated and oncologic disorders

Post Ipo Equity
71 employees
Health Care, Health and Wellness
Khondrion vs
RiboNova, Inc.
RiboNova, Inc. United States

Focused on Mitochondrial Disease & other serious rare diseases. R007 is our P2 ready asset, we also...

Series Unknown
7 employees
Biotechnology, Pharmaceutical

FAQ About Khondrion

Bringing energy to life
Khondrion was founded in 2012.
Khondrion is headquartered in The Netherlands.
Khondrion operates in the following industries: Biotechnology, Pharmaceutical.
Khondrion has approximately 7 employees.
Top alternatives and competitors to Khondrion include Praxis Precision Medicines, Inc., Kezar Life Sciences, RiboNova, Inc., Expansion Therapeutics, AZAFAROS B.V.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Khondrion and Praxis Precision Medicines, Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Khondrion and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy